Abstracts tagged "drug treatment"

Abstract Number: 1499 • 2014 ACR/ARHP Annual Meeting
Characterization of ABT-494, a Second Generation Jak1 Selective Inhibitor
Candace Graff¹, Annette Schwartz¹, Jeffrey Voss², Neil Wishart³, Lisa Olson¹, Jonathon George³, Deborah Hyland³ and Heidi Camp⁴, ¹AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²Immunology, AbbVie Pharmaceuticals, Worcester, MA, ³Abbvie Pharmaceuticals, worcester, MA, ⁴1101 Oak Street, Abbvie, Winnetka, IL
Background/Purpose Jak kinase blockade can effectively manage rheumatoid arthritis (RA) and in some cases achieve remission. However, first generation Jak inhibitors have not met expectations…
Abstract Number: 1496 • 2014 ACR/ARHP Annual Meeting
Exposure-Response Analysis for Mavrilimumab Phase2b Study in RA Patients with Informative Dropout
Chi-Yuan Wu¹, Denise Jin¹, Alex Godwood², David Close³, Lorin Roskos⁴ and Bing Wang¹, ¹Clinical Pharmacology and DMPK, Medimmune, Mountain View, CA, ²Clinical Biostatics and Data Management, MedImmune Ltd, Cambridge, United Kingdom, ³Clinical Development, MedImmune Ltd, Cambridge, United Kingdom, ⁴One MedImmune Way, Medimmune, Gaithersburg, MD
Background/Purpose: Mavrilimumab is a recombinant human monoclonal antibody which neutralizes granulocyte-macrophage colony stimulating factor (GM-CSF) activity by selectively binding to the alpha subunit of its…
Abstract Number: 272 • 2014 ACR/ARHP Annual Meeting
Factors Associated with Choice of First Biologic Among Children with Juvenile Idiopathic Arthritis: A Combined Analysis from 2 UK Paediatric Biologic Registers
Rebecca Davies¹, Lianne Kearsley-Fleet¹, Eileen Baildam², Michael W. Beresford³, Helen E. Foster⁴, Taunton R. Southwood⁵, Wendy Thomson⁶, Kimme L. Hyrich⁷, on Behalf Of The BSPAR Etanercept Cohort Study¹ and The Biologics for Children with Rheumatic Diseases (BCRD) study¹, ¹Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ³Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁴Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁵Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ⁶Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁷Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: The management of juvenile idiopathic arthritis (JIA) has been revolutionised by the introduction of biologics such as etanercept (ETN), approved in the UK in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].